Is Navoban affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2D6

Navoban is affected by pharmacogenetics through the CYP2D6 gene. Your genotype for this gene can change how your body processes Navoban, which can affect both how well it works and how well you tolerate it. The strongest evidence level on this page is Strong, based on CPIC or FDA guidelines.

What's in Navoban

tropisetron affected by CYP2D6

Affected by CYP2D6 · CPIC · Strong evidence

Read the full tropisetron genetics guide →

Tropisetron phenotype recommendations

Published guidance from CPIC on how tropisetron should be dosed or substituted based on your CYP2D6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2D6	Your body breaks down tropisetron much faster than normal, which means this anti-nausea medication may not work well enough for you. Your doctor may recommend a different anti-nausea drug instead.	CPIC Select and alternative drug not predominantly metabolized by CYP2D6 (i.e. granisetron).	Moderate
Normal Metabolizer CYP2D6	Your body processes tropisetron at a normal rate, so this anti-nausea medication should work as expected at the standard dose.	CPIC Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2D6	Your body breaks down tropisetron slightly more slowly than normal, but there is not enough evidence to change the standard dose. The usual dose is recommended.	CPIC Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	No recommendation
Poor Metabolizer CYP2D6	Your body breaks down tropisetron much more slowly than normal, but there is not enough evidence to change the standard dose. The usual dose is recommended.	CPIC Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.	No recommendation
Indeterminate CYP2D6	The impact of your genotype on response to this drug is unknown	CPIC Initiate therapy with recommended starting dose.	—
Not available CYP2D6	The impact of your genotype on response to this drug is unknown	CPIC Initiate therapy with recommended starting dose.	—

Source: CPIC

The gene behind the guidance

CYP2D6 Cytochrome P450 2D6

CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).

For most CYP2D6 drugs, poor metabolizers feel stronger effects and more side effects at standard doses, while ultrarapid metabolizers may feel almost nothing. For prodrugs like codeine, the relationship flips: poor metabolizers feel less effect because they can't activate the drug.

See all drugs affected by CYP2D6 →

Browse the full drug-class: Antiemetics.

Related medications

Find out how your genetics affect Navoban

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.